Table 1

Quality standards in the National EBUS service specification5

Quality performance indicatorThreshold
Procedure carried out within 7 working days of receipt of referral85%
Pathological results received within 3 working days of receipt of samples*
*This includes morphology and four panel immunohistochemistry
85%
Total pathway time—10 working days (from referral to receipt of pathology results*)
*This includes morphology and four panel immunohistochemistry
85%
Safety—major/minor complications<3% major
Proportion of procedures where any lymph node station was inadequate<10%
Sensitivity
Denominator=total number of patients with N2/3 metastases
Based on prevalence of N2/N3 disease
Negative predictive value
Denominator=total number of patients with a negative staging EBUS for N2/3
Based on prevalence of N2/N3 disease
Prevalence of N2/3 nodal metastases in population%
Pathological confirmation rate in advanced disease>90%
Adequate tissue for successful EGFR testing>90%
Adequate tissue for successful ALK testing>90%
Adequate tissue for successful ROS-1 testing>90%
Adequate tissue for successful PD-L1 testing>90%
NSCLC-NOS rate<10%
Proportion of cases in which a repeat sampling procedure is needed due to insufficient tissue*(* Does not include patients in which core tissue is needed for clinical trail.)<10%
  • ALK, anaplastic lymphoma kinase; EBUS, endobronchial ultrasound; EGFR, epidermal growth factor receptor; NOS, not otherwise specified; NSCLC, nonsmall cell lung cancer; PD-L1, programmed death ligand 1; ROS-1, ros UR2 sarcoma virus oncogene homolog 1 .